MULTICENTRIC CASTLEMAN DISEASE
Clinical trials for MULTICENTRIC CASTLEMAN DISEASE explained in plain language.
Never miss a new study
Get alerted when new MULTICENTRIC CASTLEMAN DISEASE trials appear
Sign up with your email to follow new studies for MULTICENTRIC CASTLEMAN DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare disease: rituximab trial in malawi
Disease control OngoingThis phase II trial tests the drug rituximab (Rituxan) as a first treatment for multicentric Castleman disease, a rare immune disorder, in 15 adults in Malawi. Some high-risk patients also receive etoposide. The study aims to see if rituximab is safe and works better than standar…
Matched conditions: MULTICENTRIC CASTLEMAN DISEASE
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 16:16 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused TerminatedThis study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…
Matched conditions: MULTICENTRIC CASTLEMAN DISEASE
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC